Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 606

Sort by

Sort Order Select

Journal Articles

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Marco Rossi, MD, Emanuela Altomare, PhD, Cirino Botta, MD, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, MD, Paola Critelli, MD, Francesco Conforti, Maria Teresa Di Martino, PhD, Bruno Paiva, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 505.

https://doi.org/10.1182/blood-2019-122429

Published: 2019

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Blood (2019) 134 (Supplement_1): 692.

https://doi.org/10.1182/blood-2019-123143

Published: 2019

Journal Articles

Structural Basis of Vitamin K Antagonism

Weikai Li, PhD, Shixuan Liu, Shuang Li

Blood (2019) 134 (Supplement_1): 482.

https://doi.org/10.1182/blood-2019-127324

Published: 2019

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Larysa Sanchez, MD, Erin Moshier, MS, Alexander Coltoff, MD, Ali Mustafa, MD, Darren Pan, MD BS, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Samir Parekh, MD, Shambavi Richard, MD, Joshua Richter, MD, Ajai Chari, MD

Blood (2019) 134 (Supplement_1): 1779.

https://doi.org/10.1182/blood-2019-128441

Published: 2019

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis

Marie Hu, MD, Gaurav Goyal, MBBS, Jason Young, MD, Karen Rech, MD, N. Nora Bennani, MD, Mithun Vinod Shah, MD PhD, Robert Vassallo, MD, Jay H Ryu, MD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 1667.

https://doi.org/10.1182/blood-2019-132104

Published: 2019

Journal Articles

BRAF V600E-Positive Precursors As Molecular Markers of Bone Marrow Involvement in Pediatric Langerhans Cell Histiocytosis

Ko Kudo, MD, Rika Kanezaki, PhD, Akie Kobayashi, MD, Tomohiko Sato, MD PhD, Takuya Kamio, MD PhD, Shinya Sasaki, MD PhD, Imamura Masaru, MD PhD, Chihaya Imai, MD PhD, Masahiro Irie, MD PhD, Yoji Sasahara, MD PhD, Kumiko Ando, MD, Harumi Kakuda, MD PhD, Takehiko Doi, MD PhD, Hiroshi Kawaguchi, MD PhD, Kazuko Kudo, MD PhD, Hirokazu Kanegane, MD PhD, Kiminori Terui, MD PhD, Tsutomu Toki, PhD, Etsuro Ito, MD PhD

Blood (2019) 134 (Supplement_1): 3588.

https://doi.org/10.1182/blood-2019-127536

Published: 2019

Journal Articles

Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass

Anna Benedetta Dalla Palma, MD, Laura Notarfranchi, MD, Jessica Crosara, MD, Mario Pedrazzoni, MD, Fabrizio Accardi, MD, Valentina Marchica, MS, Denise Toscani, PhD, Emanuela Vicario, PhD, Paola Storti, PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 1795.

https://doi.org/10.1182/blood-2019-128252

Published: 2019

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Marcio M Andrade-Campos, MD PhD, Laura Lopez de Frutos, PhD, Jorge J Cebolla, MSc, Blanca Medrano-Engay, PhD, Mercedes Roca-Espiau, PhD, Beatriz Gomez-Barrera, David Iniguez, Pilar Giraldo, PhD

Blood (2019) 134 (Supplement_1): 2323.

https://doi.org/10.1182/blood-2019-122347

Published: 2019

Journal Articles

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Shoshana Revel-Vilk, MD, Tama Dinur, PhD, Majdolen Istaiti, Dafna Frydman, DMV, Michal Becker-Cohen, MSc, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4712.

https://doi.org/10.1182/blood-2019-123000

Published: 2019

Journal Articles

Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials

Neal J Weinreb, MD, Timothy M Cox, MD, Pramod K. Mistry, MD PhD FRCP, Joel Charrow, MD, Elena Lukina, MD PhD Professor, Meredith C. Foster, ScD, M. Judith Peterschmitt, MD

Blood (2019) 134 (Supplement_1): 4859.

https://doi.org/10.1182/blood-2019-127337

Published: 2019

Journal Articles

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Martina Chiu, PhD, Denise Toscani, PhD, Emanuela Vicario, PhD, Roberta Andreoli, PhD, Giuseppe Taurino, MS, Valentina Marchica, MS, Paola Storti, PhD, Massimiliano Bianchi, PhD, Ovidio Bussolati, MD PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 4339.

https://doi.org/10.1182/blood-2019-128034

Published: 2019

Journal Articles

Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways

Daniele Tibullo, PhD, Anna Longo, PhD, Alessandra Romano, MD PhD, Alessandro Barbato, Cesarina Giallongo, PhD, Michelino Di Rosa, PhD, Carmelina Daniela Anfuso, Gabriella Lupo, Concetta Conticello, MD, Nunzio Vicario, PhD, Rosario Gulino, PhD, Rosalba Parenti, PhD, Giuseppe A. Palumbo, MD PhD, Giovanni Li Volti, MD PhD, Francesco Di Raimondo, MD

Blood (2019) 134 (Supplement_1): 4345.

https://doi.org/10.1182/blood-2019-129927

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma

Marita Westhrin, Vlado Kovcic, Albert Bondt, Stephanie Holst, Zejian Zhang, Anders Sundan, PhD, Tobias S. Slørdahl, Anders Waage, MD PhD, Manfred Wuhrer, Therese Standal

Blood (2019) 134 (Supplement_1): 4324.

https://doi.org/10.1182/blood-2019-122542

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

https://doi.org/10.1182/blood-2019-131865

Published: 2019

Journal Articles

Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment

Valentina S Caputo, Nikolaos Trasanidis, Xiaolin Xiao, Mark E Robinson, Alexia Katsarou, Kanagaraju Ponnusamy, Aristeidis Chaidos, Holger W Auner, MD PhD, Irene Roberts, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 4329.

https://doi.org/10.1182/blood-2019-125047

Published: 2019

NARROW

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Structural Basis of Vitamin K Antagonism

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis

BRAF V600E-Positive Precursors As Molecular Markers of Bone Marrow Involvement in Pediatric Langerhans Cell Histiocytosis

Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only